GLP-1s Reduce Risk of 10 Obesity-Driven Cancers, Study Says

It looks like glucagon-like peptide 1 receptor agonists (GLP-1) are pulling another trick out of their seemingly bottomless black bag. In addition to regulating blood sugar, trimming fat and cutting cardiovascular disease, they’re now associated with significant reductions in the risk of 10 obesity-related cancers.
Source: Drug Industry Daily